about
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stim...
Read More
3.17
0.23
(7.82%)
345.7K
XNAS Volume
XNAS 23 Jan, 2026 4:30 PM (EST)
Not Eligible
Expensive Valuation
Technically Moderately Bullish
Immutep Ltd (ADR) Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..